NuPathe Inc. has terminated its merger agreement with Endo Health Solutions. Endo has received a $5 million termination fee from NuPathe.

"We believe that the agreement NuPathe has signed with Teva is positive news for NuPathe stockholders and as a result we accepted the termination fee and are now proceeding to withdraw our tender offer," said Rajiv De Silva, president and CEO of Endo. "We believe our offer represented fair value for NuPathe.  We will remain disciplined in our approach to M&A and will look to deploy capital on other opportunities to create value for our shareholders."

Endo Health Solutions Inc. is a US-based specialty healthcare company with four distinct business segments that are focused on branded and generic pharmaceuticals, devices and services and provide quality products to its customers while improving the lives of patients.